Georgetown Lombardi Comprehensive Cancer Center, Washington, DC.
Moffitt Cancer Center, Tampa, FL.
JCO Oncol Pract. 2020 Oct;16(10):e1085-e1097. doi: 10.1200/JOP.19.00661. Epub 2020 May 28.
The 21-gene recurrence score (RS) assay is used to guide breast cancer treatment decisions but can be poorly understood by patients. We examined the effects of a question prompt list (QPL) on knowledge, distress, and decisional conflict related to genomic testing and treatment in early-stage breast cancer.
We describe the feasibility and acceptability of the QPL and the impact of the QPL on knowledge, distress, and decisional conflict before and after the receipt of the QPL (MEND 2, N = 65). We also compared distress and decisional conflict between women who received the QPL (MEND 2, N = 65) and a comparable group of women who did not receive the QPL who participated in an earlier observational study within the same clinics (MEND 1, N = 136).
MEND 2 participants indicated high acceptability and feasibility using the QPL. Knowledge increased post-QPL ( < .01) but did not decrease distress. Decisional conflict was lower among women in MEND 2 compared with those in MEND 1 ( < .01), with no statistically significant differences in distress.
The findings suggest that the QPL is feasible, acceptable, can improve knowledge and decrease decisional conflict in the large group of women deciding treatment while integrating RS test results.
21 基因复发评分(RS)检测可用于指导乳腺癌的治疗决策,但患者可能对此了解甚少。我们研究了问题提示清单(QPL)对早期乳腺癌患者基因组检测和治疗相关知识、痛苦和决策冲突的影响。
我们描述了 QPL 的可行性和可接受性,以及在接受 QPL 前后(MEND 2,N=65)对知识、痛苦和决策冲突的影响。我们还比较了接受 QPL(MEND 2,N=65)的女性与在同一诊所参加先前观察性研究的未接受 QPL 的可比组女性(MEND 1,N=136)之间的痛苦和决策冲突。
MEND 2 参与者表示高度接受和使用 QPL 的可行性。知识在接受 QPL 后增加(<0.01),但并未减轻痛苦。与 MEND 1 相比,MEND 2 中的女性决策冲突较低(<0.01),且痛苦无统计学差异。
这些发现表明,QPL 在整合 RS 检测结果的情况下,是一种可行的、可接受的方法,可提高正在决定治疗的大量女性的知识水平并降低决策冲突。